MENU
ALLO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Allogene Therapeutics (ALLO) Ownership - Who owns Allogene Therapeutics?
Industry: @Biotechnology
Profile
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
434.02M
P/E Ratio
N/A
Total Cash
291.56M
Projected Growth
N/A
Total Debt
85.14M
Revenue
43K
Risk (Beta)
1.04
Dividend Yield
N/A
Total Cash/Share
1.39
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
ALLO
Capitalization
434M
P/E Ratio
N/A
Risk (Beta)
1.04
Dividend Yield
N/A
Total Cash
292M
Total Cash/Share
1.39
Total Debt
85.1M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
43K
ROE
N/A
Book Value
464M
P/B Ratio
0.93
Cash Flow
N/A
Earnings
-1.55
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
210K
Current Ratio
9.35
Current Revenue Per Employee
60.94
Dividends Per Share - Security
N/A
EBITDA
-256.67M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-43.56
Shares Held By Institutions
617M
Shares Outstanding - Current
210M
Total Liabilities
125M
Total Volume MTD
N/A
Value
-1
Gain YTD
-35.514
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of allogeneic chimeric antigen receptor therapy
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com